20.03.2020 | Original Article | Ausgabe 9/2020
18F-FDG PET/CT in bone sarcoidosis: an observational study
- Zeitschrift:
-
Clinical Rheumatology
>
Ausgabe 9/2020
- Autoren:
- Lucie Demaria, Raphael Borie, Khadija Benali, Eve Piekarski, Julia Goossens, Elisabeth Palazzo, Marine Forien, Philippe Dieudé, Bruno Crestani, Sébastien Ottaviani
Abstract
Objective
Bone sarcoidosis is usually rare. Imaging procedures such as fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) can reveal bone sarcoidosis with better sensitivity than conventional radiography. We aimed to describe bone sarcoidosis involvement detected with 18F-FDG PET/CT.
Methods
This was an observational retrospective study of individuals with pulmonary sarcoidosis who underwent 18F-FDG PET/CT. According to the ATS/ERS/WASOG criteria, sarcoidosis was diagnosed by the presence of clinical and/or imaging features of sarcoidosis and evidence of non-caseating epithelioid granulomas on a biopsy. We assessed clinical and 18F-FDG PET/CT characteristics.
Results
Data for 85 patients with sarcoidosis (56.5% female, median age 47 [range 21–80] years) were analyzed. The median follow-up was 4 years. Among 56 patients, sarcoidosis occurred in more than three organs. According to ATS/ERS/WASOG criteria, bone sarcoidosis was diagnosed in 12 (14%) patients. The spine was the most commonly affected location (92%, n = 11), followed by the pelvis (67%, n = 8), sternum (33%, n = 4), humerus (25%, n = 3), and fingers (17%, n = 2). Only peripheral adenopathy was associated with bone sarcoidosis (p = 0.04). Seven patients had a 18F-FDG PET/CT follow-up, all showing a decrease of bone lesions.
Conclusion
Bone sarcoidosis occurred in 14% of patients with sarcoidosis, affecting multiple bones and mostly the axial skeleton. 18F-FDG PET/CT seems a sensitive tool for diagnosis and follow-up of bone sarcoidosis.
Key Points
• Bone sarcoidosis is not rare.
• Bone sarcoidosis affects mainly the axial skeleton.
• 18F-FDG PET/CT is useful for diagnosis and follow-up of bone sarcoidosis. |